Research

Hormonal

GLP-1 receptor agonists (semaglutide and tirzepatide) produce significantly greater average weight loss (14.9% and 18.5%, respectively) than physicians estimate (9.22%), and are associated with high rates of gastrointestinal side effects (80-90%) that are significantly underestimated by prescribers.

If you are prescribing GLP-1 agonists, ensure you are counseling patients on the high likelihood of gastrointestinal side effects (up to 90%) and the significant magnitude of weight loss (15-18%). Underestimating these factors leads to poor adherence and unrealistic expectations.

GoodSupportsHIGH confidence
Physicians reported an average patient weight loss of 9.22%, significantly lower than the 14.9% and 18.5% reported in the STEP and SURMOUNT trials, respectively. Estimated side effect rates (32.62%) were markedly lower than trial-reported rates (89.7% and 80.5%)
Srikanth Krishnan et al. · Journal of Cardiovascular Development and Disease · 2025

Why this rating

Based on large, landmark randomized controlled trials (STEP, SURMOUNT) cited in the paper.

Source

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

Srikanth Krishnan et al. · Journal of Cardiovascular Development and Disease · 2025

DOI 10.3390/jcdd12010019

cross_sectional · n=122Cited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →